Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms

About this update from Virbac Sa

Paul Martingell, Chief Executive Officer statement “Our strong start to the year underscores the competitive strength of our model, driven by a highly balanced performance across both our Companion and Farm Animal segments, with our priority ‘Supercharge’ platforms growing significantly faster at around. +15%, in line with our recently shared ‘Growing Together’ strategy. Our momentum in North America, Latin America, and IMEA was further enhanced by the successful integration of Thyronorm, cementing our growing leadership in endocrinology. While we actively manage competitive pressures in the Pacific, navigate significant global uncertainties and currency headwinds, our solid Q1 performance continues to give us confidence of our ability to deliver on our ambitious guidance for 2026.” Q1 sales by geography 1 Adjusted recurring operating income corresponds to "recurring operating income before amortization of assets arising from acquisitions". 2 CER: at constant exchange rates. This change is calculated on the actual scope of consolidation, including scope impacts arising from acquisitions ( Sasaeah ), for which the indicator in question is calculated on the basis of the previous year's exchange rate 3 CERS: constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year), and excluding material change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year 4 Supercharge platforms represent our primary growth drivers, targeting areas of high unmet need. Through these platforms, we deliver superior products and experiences across key portfolios: petfood, reproduction, dental, mobility, ear, endocrinology, and ruminants. Our first quarter consolidated revenue amounted to €384 million, representing a strong growth of +7.7% at constant exchange rates and scope compared to the same period in 2025 and +2.2% at actual rates due to significant currency headwinds. This solid organic performance is mainly driven by North America (+20.7% at CERS) and a solid expansion in the International region (+9.1% at CERS). Guidance 2026 For the full year 2026, our guidance is unchanged and we currently anticipate at constant rate and scope : In line with our reporting standards, the Thyronorm acquisition is included within the 2026 organic perimeter (constant scope) due to its low level of materiality. Consequently, our guidance accounts for Thyronorm’s contribution to both total revenue (~+1 pt of growth) and expected operating income (~+0.5 Ebit adjusted). In light of the evolving geopolitical situation in the Middle East, Virbac remains mobilized to effectively assess and manage its operational and financial exposure. Total full year revenue from countries directly at risk represents less than 0.5% of our global revenue. To date supply chain disruption remains limited and manageable within our current stock policy. We are also closely monitoring inflationary trends and we do not currently anticipate a material impact that would necessitate a revision of our outlook, as we remain confident in our ability to absorb these pressures through proactive management. About Virbac - Caring for animals together At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal pathologies. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together. More information on corporate.virbac.   Attachment

View stock analysis, news, and events for Virbac Sa